BOTHELL, Wash., Jan. 13, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) today announced that its common stock is expecting to begin trading in the over-the counter (OTC) market beginning January 13, 2011 under the trading symbol 'SCLR'. The common stock is expected to be quoted on the OTC Bulletin Board and OTCQB™ Market on that date. SCOLR's common stock will cease trading on the NYSE Amex Exchange at the close of business on January 12, 2011.
The OTCQB™ Market is a market tier for OTC-traded companies that are registered and reporting with the Securities and Exchange Commission. Quote information can be obtained by visiting www.otcmarkets.com.
About SCOLR Pharma:Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter, and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.
Forward looking statements:Any statements made in this press release that relate to plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements, including statements regarding the anticipated date of quotation of SCOLR Pharma, Inc. common stock are subject to risks and uncertainties. Factors that could cause these forward-looking statements to differ from actual results include delays in quotation, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.Contacts:Investor Relations: SCOLR Pharma, Inc. 425.368.1050
|SOURCE SCOLR Pharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved